Tag: infliximab biosimilar

Switching from an originator biologic to a biosimilar is safe for most patients with stable chronic conditions. Evidence shows no meaningful difference in efficacy or safety, though psychological factors can affect perception. Cost savings are significant, and structured patient communication improves outcomes.

Recent-posts

Pharmacy Workflow and Error Prevention Systems Explained: A Practical Guide

May, 1 2026

Falls and Medications: Which Drugs Increase Fall Risk for Seniors

Jun, 3 2026

Tolerance Development to Medications: Why Some Side Effects Disappear Over Time

Mar, 26 2026

Heart Disease Risk Factors: Age, Family History, Smoking, and What You Can Do

Nov, 28 2025

Fluocinolone for Burns: Is It Safe and Effective?

Oct, 28 2025